Table 2 Outcomes of trials investigating intensified antiplatelet therapies in patients with diabetes and CAD and/or PAD
Trial | Study population | Antiplatelet therapy | Comparator | Primary endpoint | Patients with diabetes (n) | Events in patients with diabetes (vs comparator, % of patients) |
|---|---|---|---|---|---|---|
CHARISMA [136] | Stable CAD with high atherothrombotic risk | Aspirin plus clopidogrel | Aspirin | CV mortality, MI or stroke at 28 months | 6555 | 16.5% vs 16.1% with nephropathy (HR = 1.0, 95% CI 0.8–1.3) |
DAPT [38] | Stable CAD or ACS treated with DES or BMS implantation | Aspirin plus clopidogrel or prasugrel | Aspirin | Stent thrombosis, death, MI or stroke at 30 months | 3391 | 6.6 vs 7.0 (HR = 0.92, 95% CI 0.71–1.20) |
EUCLID [39] | Symptomatic PAD or previous revascularization of the lower limbs | Ticagrelor | Clopidogrel | CV mortality, MI or stroke at 36 months | 5345 | 16.2 vs 15.6 (HR = 1.11, 95% CI 0.96–1.28)a |
PEGASUS-TIMI 54 [37] | History of MI (within the prior 3 years) and additional atherothrombotic risk factorb | Aspirin plus ticagrelor | Aspirin | CV mortality, MI or stroke at 36 months | 6806 | 10.0 vs 11.6 (HR = 0.84, 95% CI 0.72–0.99)c |
THEMIS [41] | T2DM and stable CAD receiving anti-hyperglycaemic drugs  < 6 months | Aspirin plus ticagrelor | Aspirin | CV mortality, MI or stroke at 36 months | 19,220 | 6.9 vs 7.6 (HR = 0.9, 95% CI 0.81–0.99)a |
THEMIS-PCI [40] | T2DM and stable CAD receiving anti-hyperglycaemic drugs < 6 months and previous PCI | Aspirin plus ticagrelor | Aspirin | CV mortality, MI or stroke at 40 months | 11,154 | 7.3 vs 8.6 (HR = 0.85, 95% CI 0.74–0.97) |